First dual binder of microRNA-146a and monomeric tau: a novel approach for multitargeted therapeutics for neurodegenerative diseases

We report a new approach for the development of multitargeted therapeutics for Alzheimer's disease (AD) based on dual targeting of monomeric tau and biogenesis of microRNA-146a. Compound MG-1102 displayed a superior neuroprotective activity, in comparison to mono-targeted therapeutics, which va...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Chemical communications (Cambridge, England) England), 2020-08, Vol.56 (67), p.9695-9698
Hauptverfasser:	Gabr, Moustafa T, Barbault, Florent
Format:	Artikel
Sprache:	eng
Schlagworte:	Alzheimer Disease - drug therapy Alzheimer Disease - pathology Alzheimer's disease Cell Line Cell Survival - drug effects Humans Kinetics MicroRNAs MicroRNAs - chemistry MicroRNAs - metabolism Molecular Conformation Neuroprotective Agents - chemistry Neuroprotective Agents - metabolism Neuroprotective Agents - pharmacology Neuroprotective Agents - therapeutic use Protein Binding Ribonucleic acid RNA tau Proteins - chemistry tau Proteins - metabolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	We report a new approach for the development of multitargeted therapeutics for Alzheimer's disease (AD) based on dual targeting of monomeric tau and biogenesis of microRNA-146a. Compound MG-1102 displayed a superior neuroprotective activity, in comparison to mono-targeted therapeutics, which validates the likelihood of the success of this approach in AD drug development. We report a new approach for the development of multitargeted therapeutics for Alzheimer's disease (AD) based on dual targeting of monomeric tau and biogenesis of microRNA-146a.
ISSN:	1359-7345 1364-548X
DOI:	10.1039/d0cc04249h